Status and phase
Conditions
Treatments
About
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Part A Healthy study participants
Part B Participants with moderate to severe Atopic dermatitis (AtD)
Exclusion criteria
Part A Healthy study participants
Part B Participants with moderate to severe AtD
Primary purpose
Allocation
Interventional model
Masking
273 participants in 12 patient groups, including a placebo group
Loading...
Central trial contact
UCB Cares; UCB Cares
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal